Latest California Healthline Stories
Obria, a Christian medical chain, was awarded federal family planning funds for its California clinics for the first time this year. Clinics receiving Title X funds are expected to treat and prevent sexually transmitted diseases. Obria’s prohibition against condoms means its prevention efforts rest on abstinence, even as STD rates surge.
The legal fight over the Trump administration’s new rule barring health clinics that receive federal family planning grants from referring women for abortion services played out before a divided federal appeals court Monday. Here are key takeaways.
Simple alterations — like better signs, seating, parking or door design — can make it easier for older patients to navigate health care facilities. Here are several changes doctors’ offices, clinics and hospitals could make.
An amino acid infusion called NAD is not approved by the FDA to treat addiction. Yet patients with addiction can be desperate enough to try it, at prices as high as $15,000.
The Trump administration’s policy shift on Title X family planning funds is likely to make birth control harder to get and more expensive for low-income women. It will also shift funds from organizations like Planned Parenthood to the Obria Group, which does not give women hormonal contraceptives or condoms in its clinics.
An encounter with a cat led to rabies shots and provided yet another illustration of how confusing, contrary and expensive the American health care system is.
California’s stem cell agency, created by a $3 billion bond measure 15 years ago, is almost out of money. Its supporters plan to ask voters for even more funding next year, even though no agency-funded treatments have been approved for widespread use.
A small health center in Goshen, Ind., near the border with Michigan, puts “listening to patients’ stories” first. “The rest is housekeeping.”
Tennessee company’s Medicare billings for urine tests were examined by Kaiser Health News in 2017.
Regenexx, which runs a string of clinics, says stem cell injections can save employers a lot of money, but critics say there’s no proof.